Study advances cancer precision therapies by identifying patients who benefit from bexmarilimab treatment

Researchers at the University of Turku, Finland, have taken a step towards more personalized and effective cancer treatments. A new study has identified the conditions under which the antibody drug bexmarilimab can activate the body's own defense system against cancer, and how to identify patients who will benefit from the drug.

👉 Full Story